June 3, 2024
Pediatric Research Update | Treatment of Hypothalamic Obesity
Share this post
Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. This month’s update addresses treatment of hypothalamic obesity.
Treatment of Hypothalamic Obesity in People with Hypothalamic Injury: New Drugs are on the Horizon #
Article Summary
Hypothalamic obesity (HO) is a complex disorder resulting from either monogenic cause or injury of the hypothalamus. Lifestyle intervention alone is usually ineffective. This article aims to discuss newer treatments for HO.
Article Review
The article addresses the complex condition of hypothalamic obesity (HO). It briefly discusses the two types of HO which are genetic or acquired. The authors primarily concentrate on acquired HO, which arises from hypothalamic lesion often treated through surgery and/ or radiation. Craniopharyngioma (CP) is identified as the most prevalent cause of acquired HO.
In discussing the pathophysiology and phenotypes of acquired HO, the authors describe a syndrome characterized by excessive weight gain resulting from hyperphagia potentially due to leptin resistance and deficiencies in downstream energy regulation neuroendocrine pathway. Additional features include decreased sympathetic activity, low energy expenditure, temperature dysregulation, and increased energy storage in adipose tissue, all of which are very similar in patients with monogenic cause of HO.
The article highlights the lack of FDA approved treatment specifically for HO but reviews existing medications currently approved for general obesity such as GLP-1 receptor agonists (GLP1Ras) and combination Phentermine/ Topiramate. It also mentions drugs that had undergone clinical trials for HO including oxytocin and Tesofensine. Currently, Setmelanotide, a MC4R agonist approved for certain monogenic obesity forms is undergoing clinical trials for acquired HO.
As obesity pharmacotherapy is rapidly evolving, the development of newer drugs is anticipated. Tirzepitide, approved for adult Type 2 diabetes, has demonstrated 20% weight loss, while Retatrutide, a triple agonist (GIP, GLP and glucagon) is currently in a phase 2 clinical trial showing 24.2% weight loss over 48 weeks.
Treatment for HO should be tailored based on phenotype spectrum as previously discussed, recommending a switch to another drug or combination therapy if there is no response after three months.
As a final statement, authors propose that MC4R agonism could represent a new standard of treatment for HO.
Get the latest news about OMA’s live educational events and online courses.
Subscribe-
Roth CL, Zenno A. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. Front Endocrinol (Lausanne). 2023 Sep 13;14:1256514. doi: 10.3389/fendo.2023.1256514. PMID: 37780616; PMCID: PMC10533996.
Article reviewed by:
Jacqueline T. Chan, MD, FAAP, DABOM
Dr. Jacqueline Chan completed her Pediatric residency at Sinai Children's Hospital, and her Pediatric endocrinology Fellowship at University Of Illinois Chicago/ Rush University.
Dr. Chan is certified in Pediatrics, Pediatric Endocrinology and Obesity Medicine. She was an assistant professor of pediatrics faculty at the Children’s hospital of Georgia for 5 years. She has provided multiple education lecture series and podcasts about various endocrine and metabolic issues. In addition, she has published multiple peer reviewed articles and is an active member of the Obesity Medicine Association Pediatric Committee.
Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah and is in the Division of Pediatric Endocrinology at Primary Children´s Medical Center where Dr. Chan and is leading a multidisciplinary team for children with obesity. Her interest is on comorbidities associated with pediatric obesity mainly Type 2 diabetes and lipid disorders, as well as Hypothalamic obesity.
Pediatric Research Update: Physical Activity Patterns and Associations in Infants and Toddlers
The most increase in physical activity (PA) was found to be from infancy to 24 months and then tended to plateau. Greater screen time exposure was associated with a slower rate of PA increase between 6 and 24 months of age. Based on these findings, clinicians should consider integrating PA anticipatory guidance into well-child visits beginning in early infancy, with attention to screen time limits and opportunities for active play. In their original article, Longitudinal Change in Physical Activity in Children 6 to 36 Months of Age , Pate and colleagues not only present the developmental pattern for PA in this age group but also highlight factors that may hinder or promote PA development. Interestingly, screen time was associated with higher PA levels at 6 months but with a slower rate of PA growth by 24 months, suggesting that the negative impact of screen exposure on physical activity accumulates over time rather than appearing immediately. Longitudinal Change in Physical Activity in Children 6 to 36 Months of Age.
Pediatric Research Update: Obesity and Mental Health in Childhood Adolescence
Article Summary This scoping review highlights the complex, bidirectional relationship between pediatric obesity and mental health, emphasizing depression, psychosocial mediators, and the importance of integrated behavioral and medical interventions in pediatric obesity care. Read the Full Article Article Review Childhood and adolescent obesity is increasingly recognized as a chronic, relapsing condition with significant mental and behavioral health implications. In Obesity and Mental Health in Childhood and Adolescence: A Scoping Review of Recent Scientific Evidence , Morales-Suárez-Varela et al. review recent literature examining the relationship between pediatric obesity and mental health outcomes, with particular attention on depressive symptoms. This review reinforces the importance of addressing mental health and providing mental health treatment as a core component of pediatric obesity care rather than adjunctive care alone. This scoping review synthesizes evidence published over the last decade and highlights the complex, bidirectional relationship between obesity and mental health.
Pediatric Research Update: Pediatric Metabolic and Bariatric Surgery and Antiobesity Medications
Article Summary Treatment Across the Care Continuum in Adolescent Obesity Management: This article reviews the complexity of treating adolescents affected by obesity using antiobesity medications and metabolic bariatric surgery, the potential role of concurrent versus singular treatment strategies and highlights and the need for further research to define optimal timing of these therapies in the adolescent population. Read the Full Article Article Review The treatment landscape for adolescents affected by obesity in the United States has changed dramatically over the past few years. This article highlights the growing impact of adolescent obesity, current information, epidemiology, unique features of adolescent obesity, barriers to care and reviews current treatment options, including antiobesity pharmacotherapy and metabolic bariatric surgery (MBS). Expanding pediatric obesity programs that offer comprehensive care, including lifestyle interventions, anti-obesity medications, and adolescent MBS may help optimize treatment strategies and improve long-term outcomes for adolescents with obesity. Reframing obesity treatment in the adolescent population using a chronic disease model would shift the perspective from viewing treatment as a one-time intervention to recognizing it as part of a continuous, long-term care process. Adopting this model may improve the sustainability of weight management, support the prevention and treatment of weight regain, and promote better long-term health outcomes for adolescents living with obesity. Implications for adult and pediatric obesity specialists include advocating for patients access to evidence-based care, including treatment for adolescents affected by obesity and its associated comorbidities.